▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #939 by analyst upside · 2026-06-27
ZLAB
Zai Lab Limited
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+85.0%
implied upside to consensus target
Current Price $18.0
Consensus Target $33.3
Bull Target $52.0
Bear Target $21.6
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
9
Hold
1
Sell
0
52-Week Low $15.96
52-Week High $41.2
YTD Return +3.9%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -10.3x
EPS (TTM) $-1.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $453M
Profit Margin -39.3%
52-WEEK RANGE
52-Week Low $15.96
52-Week High $41.2
Current Price $18.0
Bear Target $21.6
Bull Target $52.0
● Now $18.0 ● Target $33.3
TRADING DATA
Avg Volume 869K
YTD Return +3.9%
Analyst Count 12
Consensus Buy
Upside to Target +85.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Zai Lab Limited (ZLAB) is currently trading at $18.0 with a Wall Street consensus price target of $33.3, implying potential upside of 85.0% over the next 12 months. 12 analysts currently cover ZLAB, with a consensus rating of Buy — 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $52.0, while the most cautious has a target of $21.6.

ZLAB operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 3.9% year-to-date and is currently trading near the lower end of its 52-week range of $15.96 – $41.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +101.1%
ADMA Biologics, Inc.
$2B · P/E 12.9x · Buy
TMDX +71.4%
TransMedics Group, Inc.
$2B · P/E 15.7x · Buy
GTBIF +112.0%
Green Thumb Industries Inc.
$2B · P/E 14.2x · Buy
INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy
HCM +124.5%
HUTCHMED (China) Limited
$2B · P/E 3.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ZLAB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup — Reiterated
Buy → Buy 2026-05-08 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-03-18 43% win rate (7 calls)
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-02-27 40% win rate (10 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-02-05 43% win rate (7 calls)
UBS ● Initiated
Buy 2026-01-07 33% win rate (6 calls)
Citigroup — Reiterated
Buy → Buy 2025-08-11 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2025-06-30 29% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-03-27 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →